Alphyn Closes $25M Oversubscribed Series B Financing Round to Advance Dermatology Pipeline

阿尔芬完成超额认购的2500万美元B轮融资，以推进皮肤病学产品线。

Financing funds the global Phase 2b clinical trial in atopic dermatitis and Phase 2 clinical program in molluscum contagiosum

融资资金将用于全球特应性皮炎的2b期临床试验和传染性软疣的2期临床项目。

ANNAPOLIS, Md., December 12, 2025-- Alphyn Biologics, Inc., a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, today announced the close of its $25 million, twice-oversubscribed Series B financing. Proceeds will fund the Phase 2b global clinical trial of Alphyn's lead drug candidate, Zabalafin Hydrogel, for atopic dermatitis (AD), initiate a second Phase 2 clinical program for the treatment of the molluscum contagiosum virus (MCV), and expand the company's supply of drug raw material..

马里兰州安纳波利斯，2025年12月12日——Alphyn Biologics, Inc.是一家处于临床阶段的皮肤病学公司，致力于开发首创的多靶点治疗药物®。该公司今天宣布成功完成其超额认购两倍的2500万美元B轮融资。所得款项将用于资助Alphyn主要候选药物Zabalafin水凝胶针对特应性皮炎（AD）的2b期全球临床试验，启动第二个针对传染性软疣病毒（MCV）治疗的2期临床项目，并扩大公司的药物原料供应。

The round was led by QCA Investment Group and included existing investors Angel Physicians Fund, Serial Stage Venture Partners, a corporate fund, and several new investors.

本轮融资由QCA投资集团领投，现有投资者天使医生基金、连续阶段风险合伙人、一家企业基金以及数位新投资者跟投。

'We are incredibly grateful for the support of our current and new investors. This financing reflects their confidence in our Multi-Target Therapeutic Drug Platform and our unique and highly differentiated drug candidates for atopic dermatitis and the molluscum contagiosum virus,' said Alphyn CEO Neal Koller.

“我们对现有投资者和新投资者的支持深表感激。此次融资反映了他们对我们多靶点治疗药物平台以及针对特应性皮炎和传染性软疣病毒的独特且高度差异化的候选药物的信心，”Alphyn首席执行官Neal Koller表示。

'We are well-positioned to rapidly advance Zabalafin Hydrogel towards our next key milestones - two pivotal Phase 3 trials - while broadening our pipeline of breakthrough therapies for skin diseases.'.

“我们有能力快速推进Zabalafin水凝胶朝着下一个关键里程碑——两项关键的III期试验迈进，同时拓展我们在皮肤病突破性治疗领域的研发管线。”

Alphyn is developing Zabalafin Hydrogel as the first therapeutic to directly treat the distinct but interconnected drivers of AD - inflammation, itch, bacteria, and dry skin - and to directly treat the distinct but interconnected drivers of MCV – the virus itself, itch, inflammation and, in many sufferers, dermatitis (molluscum rash) and the added bacterial infection with its associated pain.

Alphyn 正在开发 Zabalafin 水凝胶，作为首个直接治疗 AD 的不同但相互关联的驱动因素（炎症、瘙痒、细菌和干燥皮肤）的疗法，并直接针对 MCV 的不同但相互关联的驱动因素——病毒本身、瘙痒、炎症，以及在许多患者中出现的皮炎（传染性软疣疹）和伴随细菌感染及其相关疼痛。

Drugs on the market and being studied in clinical trials for both diseases directly target only one of the disease drivers, leaving the body to later fight the others. Zabalafin Hydrogel, with its expected strong efficacy and patient tolerability profile, has the potential for sustained management and long-term control of these diseases.

市场上的药物以及针对这两种疾病在临床试验中研究的药物都只能直接作用于其中一个致病因素，而身体需要随后对抗其他因素。Zabalafin水凝胶凭借其预期的强大疗效和患者耐受性，有潜力实现对这些疾病的持续管理和长期控制。

For MCV, it has the potential to be the first direct antiviral drug that is safe, gentle and effective, and therefore the first real treatment option for the millions of children afflicted with this disease. Current marketed therapeutics destroy the skin and are blistering and painful for patients..

对于MCV，它有潜力成为第一个安全、温和且有效的直接抗病毒药物，因此也是数百万患有这种疾病的儿童的第一个真正的治疗选择。目前市场上的治疗药物会破坏皮肤，给患者带来水泡和痛苦。

'Alphyn is breaking new ground with a first-in-class, natural topical therapeutic that is expected to directly addresses all of AD's problems and have the potential for long-term, continuous use,' said Tony Shipley, chairman of Alphyn's lead investor, QCA Investment Group. 'With an experienced leadership team and their continued strong execution, Alphyn is poised to meet two tremendous market needs and bring patients a highly innovative new therapy for AD and MCV.'.

“Alphyn正在开创先河，推出了一种首创的、天然的局部治疗药物，预计能够直接解决AD的所有问题，并具有长期持续使用的潜力，”Alphyn的主要投资者QCA投资集团董事长托尼·希普利表示。“凭借经验丰富的领导团队和他们持续有力的执行力，Alphyn准备满足两大市场需求，为AD和MCV患者带来一种极具创新性的新疗法。”

ABOUT ALPHYN BIOLOGICS

关于ALPHYN生物制品公司

Alphyn Biologics, Inc. is a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics® for severe and prevalent skin diseases based on its Zabalafin Platform. Its lead product candidate, Zabalafin Hydrogel, is being developed as a topical treatment for atopic dermatitis (AD), the most common form of eczema, and the molluscum contagiosum virus (MCV), an unsightly, pruritic (itchy), and highly contagious skin infection predominantly in children..

Alphyn生物公司是一家临床阶段的皮肤病学公司，基于其Zabalafin平台开发用于严重和常见皮肤病的一流多靶点治疗药物®。其主要候选产品Zabalafin水凝胶正在被开发为一种局部治疗药物，用于特应性皮炎（AD，最常见的一种湿疹）以及传染性软疣病毒（MCV，一种难看、瘙痒且高度传染的皮肤感染，主要见于儿童）。

Zabalafin Hydrogel is unique in its ability to directly treat all the interconnected problems of both AD and MCV. For AD, Zabalafin Hydrogel directly treats the immuno-inflammatory component of the disease, directly treats pruritus (itch), directly treats the bacterial component of AD, and directly treats xerosis (dry skin).

Zabalafin Hydrogel 的独特之处在于它能够直接治疗 AD 和 MCV 的所有相互关联的问题。对于 AD，Zabalafin Hydrogel 直接治疗该疾病的免疫炎症成分，直接缓解瘙痒（痒），直接处理 AD 的细菌成分，并直接改善干燥皮肤（干皮症）。

For MCV, Zabalafin directly targets the virus itself, directly treats itch, directly treats inflammation and, in many sufferers, directly treats dermatitis (molluscum rash) and the added problem of bacterial infection with its associated pain..

对于MCV，Zabalafin直接靶向病毒本身，直接治疗瘙痒，直接治疗炎症，并且在许多患者中直接治疗皮炎（传染性软疣疹）以及伴随的细菌感染和相关疼痛。

Alphyn's Zabalafin Platform has multiple bioactive compounds and, therefore, multiple mechanisms of action to support treatment of an individual disease in multiple ways, for anticipated improved efficacy, and to provide a robust pipeline of dermatologic therapeutics that have potential advantages in efficacy, safety, side effect, patient tolerability, and regulatory marketing authorization.

阿尔芬的Zabalafin平台含有多种生物活性化合物，因此具有多种作用机制，可以多方面支持单一疾病的治疗，预期能提高疗效，并提供一系列皮肤病治疗药物，这些药物在疗效、安全性、副作用、患者耐受性以及监管和市场授权方面具有潜在优势。

Alphyn is based in Annapolis, Maryland, and Cincinnati, Ohio, and has wholly owned subsidiaries in Australia and Austria. The company became operational in 2020 and has raised approximately $34 million..

阿尔芬公司总部位于马里兰州安纳波利斯和俄亥俄州辛辛那提，并在澳大利亚和奥地利拥有全资子公司。该公司于2020年开始运营，已筹集了约3400万美元。